Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.

Research output: Contribution to journalArticle

Standard

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. / Insel, Richard A; Dunne, Jessica L; Atkinson, Mark A; Chiang, Jane L; Dabelea, Dana; Gottlieb, Peter A; Greenbaum, Carla J; Herold, Kevan C; Krischer, Jeffrey P; Lernmark, Åke; Ratner, Robert E; Rewers, Marian J; Schatz, Desmond A; Skyler, Jay S; Sosenko, Jay M; Ziegler, Anette-G.

In: Diabetes Care, Vol. 38, No. 10, 2015, p. 1964-1974.

Research output: Contribution to journalArticle

Harvard

Insel, RA, Dunne, JL, Atkinson, MA, Chiang, JL, Dabelea, D, Gottlieb, PA, Greenbaum, CJ, Herold, KC, Krischer, JP, Lernmark, Å, Ratner, RE, Rewers, MJ, Schatz, DA, Skyler, JS, Sosenko, JM & Ziegler, A-G 2015, 'Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.', Diabetes Care, vol. 38, no. 10, pp. 1964-1974. https://doi.org/10.2337/dc15-1419

APA

Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., Ratner, R. E., Rewers, M. J., Schatz, D. A., Skyler, J. S., Sosenko, J. M., & Ziegler, A-G. (2015). Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 38(10), 1964-1974. https://doi.org/10.2337/dc15-1419

CBE

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler A-G. 2015. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 38(10):1964-1974. https://doi.org/10.2337/dc15-1419

MLA

Vancouver

Author

Insel, Richard A ; Dunne, Jessica L ; Atkinson, Mark A ; Chiang, Jane L ; Dabelea, Dana ; Gottlieb, Peter A ; Greenbaum, Carla J ; Herold, Kevan C ; Krischer, Jeffrey P ; Lernmark, Åke ; Ratner, Robert E ; Rewers, Marian J ; Schatz, Desmond A ; Skyler, Jay S ; Sosenko, Jay M ; Ziegler, Anette-G. / Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. In: Diabetes Care. 2015 ; Vol. 38, No. 10. pp. 1964-1974.

RIS

TY - JOUR

T1 - Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.

AU - Insel, Richard A

AU - Dunne, Jessica L

AU - Atkinson, Mark A

AU - Chiang, Jane L

AU - Dabelea, Dana

AU - Gottlieb, Peter A

AU - Greenbaum, Carla J

AU - Herold, Kevan C

AU - Krischer, Jeffrey P

AU - Lernmark, Åke

AU - Ratner, Robert E

AU - Rewers, Marian J

AU - Schatz, Desmond A

AU - Skyler, Jay S

AU - Sosenko, Jay M

AU - Ziegler, Anette-G

PY - 2015

Y1 - 2015

N2 - Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of β-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of β-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease.

AB - Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of β-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of β-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease.

U2 - 10.2337/dc15-1419

DO - 10.2337/dc15-1419

M3 - Article

C2 - 26404926

VL - 38

SP - 1964

EP - 1974

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 10

ER -